article thumbnail

BONESUPPORT CEO Emil Billbäck Shares Insights About Cerament G, the New Bone Void Filler Launching in the US

XTalks

BONESUPPORT received market authorization from the FDA for Cerament G, the first and only bone graft with antibiotic elution that is approved for the US market. BONESUPPORT has recently received market authorization from the US Food and Drug Administration (FDA) for Cerament G, its bone graft with antibiotic elution.

Filler 98
article thumbnail

How MALK Organics Is Leading the Plant-Based Milk Revolution

XTalks

Let’s explore MALK Organics’ history, its competitors and what sets it apart in a fiercely competitive market. Its recent internal Series B investment round , led by Benvolio Group and Rotor Capital, underlines the brand’s significant growth and market potential. Distribution is another area where MALK Organics shines.

Branding 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ company

pharmaphorum

Prior to the $63 billion takeover by AbbVie, Allergan’s biggest product was botulinum toxin product Botox, best known as a wrinkle and migraine treatment, and that headed a sizeable medical aesthetics portfolio at the company which also included dermal filler products like Juvederm.

Botox 115
article thumbnail

Bone Void Filler Cerament G: The Combination Product by BONESUPPORT Gets Market Authorization from the FDA

XTalks

Ceramanet G, a bone void filler with the antibiotic gentamicin, fills bone voids and immediately begins bone healing with protection. Cerament G is a bone void filler treatment that can fill the gaps in the affected bones and simultaneously deliver the antibiotic gentamicin to reduce the risk of reinfection. mg/mL of cerament paste.

Filler 98
article thumbnail

New Section 804 Drug Import Rule Does Not Allow Foreign Versions of FDA-Approved Drugs

Pharmacy Checkers

After all, the law only allows for the sale of FDA-approved drugs within the United States. A drug is considered “FDA-approved” when the FDA approves the drug application of a manufacturer to market that drug in the United States. But the Canadian drug includes a different binder or filler as inactive ingredients.

article thumbnail

Some Talc Products Contain Asbestos: Study

The Pharma Data

“The lab repeatedly finds asbestos in products made with talc, including cosmetics marketed to children. Talc is often used in cosmetics as a filler or to improve texture or absorb moisture. In May, Johnson & Johnson announced it would end the sale of its talc-based baby powder in the United States and Canada.

article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

As part of the License Agreement, Crescita will receive an upfront payment in cash of US$125,000 and will be eligible for regulatory and sales milestones of up to US$1.0 million and US$1.8 About Juyou Bio – Technology Co. Juyou Bio-Technology Co.,